title: Measuring the cost of chemotherapy is important, but it is not enough.
authors.forename: P
authors.initials: P
authors.lastname: Marino
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D000529:Complementary Therapies / Q000191:economics; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D000077143:Docetaxel; D016527:Drug Costs; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000191:economics; D017239:Paclitaxel / Q000627:therapeutic use; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use; D035703:Therapies, Investigational / Q000191:economics
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel